369 related articles for article (PubMed ID: 12097280)
21. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture.
Tanizawa A; Pommier Y
Cancer Res; 1992 Apr; 52(7):1848-54. PubMed ID: 1312902
[TBL] [Abstract][Full Text] [Related]
22. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content.
Woessner RD; Eng WK; Hofmann GA; Rieman DJ; McCabe FL; Hertzberg RP; Mattern MR; Tan KB; Johnson RK
Oncol Res; 1992; 4(11-12):481-8. PubMed ID: 1338578
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Ng CE; Cybulski SE; Bussey AM; Aubin RA; Raaphorst GP
Anticancer Res; 1998; 18(4C):3119-26. PubMed ID: 9713520
[TBL] [Abstract][Full Text] [Related]
24. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
25. Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Chen BM; Chen JY; Kao M; Lin JB; Yu MH; Roffler SR
Gynecol Oncol; 2000 Nov; 79(2):272-80. PubMed ID: 11063656
[TBL] [Abstract][Full Text] [Related]
26. Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Gradzka I; Szumiel I
Cell Biochem Funct; 1996 Sep; 14(3):163-71. PubMed ID: 8888569
[TBL] [Abstract][Full Text] [Related]
27. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Fujimori A; Hoki Y; Popescu NC; Pommier Y
Oncol Res; 1996; 8(7-8):295-301. PubMed ID: 8938793
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Goldwasser F; Bae I; Valenti M; Torres K; Pommier Y
Cancer Res; 1995 May; 55(10):2116-21. PubMed ID: 7743511
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Hentze H; Latta M; Künstle G; Dhakshinamoorthy S; Ng PY; Porter AG; Wendel A
Hepatology; 2004 May; 39(5):1311-20. PubMed ID: 15122760
[TBL] [Abstract][Full Text] [Related]
30. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Fujimori A; Harker WG; Kohlhagen G; Hoki Y; Pommier Y
Cancer Res; 1995 Mar; 55(6):1339-46. PubMed ID: 7882333
[TBL] [Abstract][Full Text] [Related]
31. [Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor].
Zhang Q; Zhou K; Ling G
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1997 Dec; 32(6):332-5. PubMed ID: 10743104
[TBL] [Abstract][Full Text] [Related]
32. Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Sukhanova A; Grokhovsky S; Zhuze A; Devy J; Pluot M; Oleinikov V; Nabiev I
Anticancer Res; 2003; 23(3B):2609-15. PubMed ID: 12894548
[TBL] [Abstract][Full Text] [Related]
33. The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles.
Bailly C; Carrasco C; Hamy F; Vezin H; Prudhomme M; Saleem A; Rubin E
Biochemistry; 1999 Jul; 38(27):8605-11. PubMed ID: 10393535
[TBL] [Abstract][Full Text] [Related]
34. [The effect of EB virus bhrfl gene expressing on the topoisomerase I expression in nasopharyngeal carcinoma cell line].
Huang H; Pan X; Zhou J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Jun; 15(2):128-31. PubMed ID: 11436640
[TBL] [Abstract][Full Text] [Related]
35. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
Gupta RS; Gupta R; Eng B; Lock RB; Ross WE; Hertzberg RP; Caranfa MJ; Johnson RK
Cancer Res; 1988 Nov; 48(22):6404-10. PubMed ID: 2846151
[TBL] [Abstract][Full Text] [Related]
36. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines.
Borovitskaya AE; D'Arpa P
Oncol Res; 1998; 10(5):271-6. PubMed ID: 9802062
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Yanase K; Sugimoto Y; Tsukahara S; Oh-Hara T; Andoh T; Tsuruo T
Jpn J Cancer Res; 2000 May; 91(5):551-9. PubMed ID: 10835501
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of camptothecin resistance by human topoisomerase I mutations.
Chrencik JE; Staker BL; Burgin AB; Pourquier P; Pommier Y; Stewart L; Redinbo MR
J Mol Biol; 2004 Jun; 339(4):773-84. PubMed ID: 15165849
[TBL] [Abstract][Full Text] [Related]
39. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
40. Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.
Fan Y; Weinstein JN; Kohn KW; Shi LM; Pommier Y
J Med Chem; 1998 Jun; 41(13):2216-26. PubMed ID: 9632354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]